نتایج جستجو برای: ®gleevec

تعداد نتایج: 513  

Journal: :Cancer research 2003
Jeffery S Russell Kristin Brady William E Burgan Michael A Cerra Kelli A Oswald Kevin Camphausen Philip J Tofilon

Rad51 is an essential component of the homologous DNA repair pathway and has been implicated as a determinant of cellular radiosensitivity. Gleevec is a relatively specific inhibitor of c-Abl, a tyrosine kinase that can play a role in the regulation Rad51. The aim of this study was to determine the effects of Gleevec on Rad51 levels and the radiosensitivity of two human glioma cell lines and a ...

2016
Sun-Sil Choi Eun-Sun Kim Ji-Eun Jung David P. Marciano Ala Jo Ja Young Koo Soo Youn Choi Yong Ryoul Yang Hyun-Jun Jang Eung-Kyun Kim Jiyoung Park Hyug Moo Kwon In Hee Lee Seung Bum Park Kyung-Jae Myung Pann-Ghill Suh Patrick R. Griffin Jang Hyun Choi

Blocking phosphorylation of peroxisome proliferator-activated receptor (PPAR)γ at Ser(273) is one of the key mechanisms for antidiabetes drugs to target PPARγ. Using high-throughput phosphorylation screening, we here describe that Gleevec blocks cyclin-dependent kinase 5-mediated PPARγ phosphorylation devoid of classical agonism as a PPARγ antagonist ligand. In high fat-fed mice, Gleevec improv...

2006
Gerald V. Denis

word count: 135 Suggested running head: " Gleevec and chemoresistance " 2 Abstract Gleevec is an important, new, molecularly targeted, anti-cancer agent that has demonstrated clinical efficacy in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST). These malignancies develop after constitutive activation of Abelson (Abl) or Abl-like tyrosine kinases; Gleevec is a specif...

Journal: :Science-Business eXchange 2012

2012
Jingxuan Pan

In some types of tumors, malignant cells are highly dependent on the constitutive activation of a certain protein encoded by oncogene, despite existence of additional carcinogenic genetic changes. This phenomenon is referred to oncogene addiction. Typical examples include cytoplasmic tyrosine kinase Bcr-Abl in chronic myeloid leukemia (CML), receptor tyrosine kinase KIT in systemic mastocytosis...

Journal: :Science-Business eXchange 2008

Journal: :Cancer research 2002
Ramadevi Nimmanapalli Erica O'Bryan Mei Huang Purva Bali Pearlie Kay Burnette Thomas Loughran James Tepperberg Richard Jove Kapil Bhalla

Using human acute leukemia HL-60/Bcr-Abl (with ectopic expression of p185 Bcr-Abl) and K562 cells (with endogenous expression of p210 Bcr-Abl) subjected to a continuous selection pressure of up to 1.0 micro M Gleevec (imatinib mesylate, STI-571), we have isolated Gleevec-resistant K562 R (+Bcr-Abl), K562 R (-Bcr-Abl), and HL-60/Bcr-Abl R cells, which display disparate level and activity of Bcr-...

2003
Pep Charusanti Xiao Hu Luonan Chen Daniel Neuhauser Joseph J. DiStefano

A mathematical model is presented that describes several signaling events that occur in cells from patients with chronic myeloid leukemia, i.e. autophosphorylation of the Bcr-Abl oncoprotein and subsequent signaling through the Crkl pathway. Dynamical effects of the drug STI-571 (Gleevec) on these events are examined, and a minimal concentration for drug effectiveness is predicted by simulation...

Journal: :Nature Biotechnology 2013

2014
Yen-Lin Lin Yilin Meng Lei Huang Benoît Roux

Gleevec is a potent inhibitor of Abl tyrosine kinase but not of the highly homologous c-Src kinase. Because the ligand binds to an inactive form of the protein in which an Asp-Phe-Gly structural motif along the activation loop adopts a so-called DFG-out conformation, it was suggested that binding specificity was controlled by a "conformational selection" mechanism. In this context, the binding ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید